share_log

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K：重大事件
美股sec公告 ·  05/03 04:31
牛牛AI助理已提取核心訊息
Senti Biosciences, Inc., a Delaware-incorporated biotechnology company, has announced significant changes to its executive team in a recent Form 8-K filing with the SEC. Timothy Lu, M.D., Ph.D., currently serving as the CEO and President, has been appointed as the interim principal financial officer and principal accounting officer, effective May 4, 2024. This appointment follows the Board's approval on April 26, 2024, and will last until a permanent successor is appointed or until Lu's earlier departure from the role. Additionally, Yvonne Li has been appointed as the Interim Chief Financial Officer, also effective May 4, 2024. Li's appointment will become official immediately after the filing of the company's Quarterly Report for the fiscal quarter ended March 31, 2024. In conjunction with her appointment, Li has entered into a consulting agreement with Senti Biosciences, which includes a consulting fee of $350 per hour and a maximum aggregate payment of $370,000. The company plans to provide a full description of the Li Consulting Agreement in its upcoming Quarterly Report for the fiscal quarter ending June 30, 2024.
Senti Biosciences, Inc., a Delaware-incorporated biotechnology company, has announced significant changes to its executive team in a recent Form 8-K filing with the SEC. Timothy Lu, M.D., Ph.D., currently serving as the CEO and President, has been appointed as the interim principal financial officer and principal accounting officer, effective May 4, 2024. This appointment follows the Board's approval on April 26, 2024, and will last until a permanent successor is appointed or until Lu's earlier departure from the role. Additionally, Yvonne Li has been appointed as the Interim Chief Financial Officer, also effective May 4, 2024. Li's appointment will become official immediately after the filing of the company's Quarterly Report for the fiscal quarter ended March 31, 2024. In conjunction with her appointment, Li has entered into a consulting agreement with Senti Biosciences, which includes a consulting fee of $350 per hour and a maximum aggregate payment of $370,000. The company plans to provide a full description of the Li Consulting Agreement in its upcoming Quarterly Report for the fiscal quarter ending June 30, 2024.
特拉華州註冊成立的生物技術公司Senti Biosciences, Inc. 在最近向美國證券交易委員會提交的8-K表格中宣佈了其執行團隊的重大變動。Timothy Lu，醫學博士，現任首席執行官兼總裁，已被任命爲臨時首席財務官兼首席會計官，自2024年5月4日起生效。這項任命是在董事會於2024年4月26日批准之後進行的，將持續到任命永久繼任者或盧提前離職爲止。此外，李怡被任命爲臨時首席財務官，同樣自2024年5月4日起生效。在公司提交截至2024年3月31日的財季季度報告後，李的任命將立即正式生效。在接受任命的同時，李還與Senti Biosciences簽訂了諮詢協議，其中包括每小時350美元的諮詢費和最高37萬美元的總付款。該公司計劃在即將發佈的截至2024年6月30日的財季季度報告中對李諮詢協議進行全面描述。
特拉華州註冊成立的生物技術公司Senti Biosciences, Inc. 在最近向美國證券交易委員會提交的8-K表格中宣佈了其執行團隊的重大變動。Timothy Lu，醫學博士，現任首席執行官兼總裁，已被任命爲臨時首席財務官兼首席會計官，自2024年5月4日起生效。這項任命是在董事會於2024年4月26日批准之後進行的，將持續到任命永久繼任者或盧提前離職爲止。此外，李怡被任命爲臨時首席財務官，同樣自2024年5月4日起生效。在公司提交截至2024年3月31日的財季季度報告後，李的任命將立即正式生效。在接受任命的同時，李還與Senti Biosciences簽訂了諮詢協議，其中包括每小時350美元的諮詢費和最高37萬美元的總付款。該公司計劃在即將發佈的截至2024年6月30日的財季季度報告中對李諮詢協議進行全面描述。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。